About Harmony Biosciences
Harmony Biosciences is a publicly listed company based in Plymouth Meeting (United States) founded in 2017. Harmony Biosciences has raised $345 million across 6 funding rounds from investors including Fidelity Investments, Orbimed and HBM Healthcare Investments. The company has 268 employees. Harmony Biosciences has completed 1 acquisition, including Zynerba Pharma. Its website harmonybiosciences.com draws about 10 thousand monthly visits. Harmony Biosciences offers products and services including ZYN002. Its focus areas include Life Sciences, Rare Diseases, Drugs and CNS. Its legal entity is Harmony Biosciences Management, Inc. Its competitors include QurAlis, Passage Bio and MindMed; 2 of its 3 listed competitors have raised funding.
Company details
Developer of therapeutics for rare neurological diseases. The company is engaged in the research, development, and commercialization of novel treatments for rare diseases mainly CNS disorders including Wakix for Narcolepsy.
- Headquarters Plymouth Meeting, United States
- Employees 268
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website harmonybiosciences.com
- Social LinkedIn X Instagram
- Legal Name Harmony Biosciences Holdings, Inc.
- Annual Revenue$868.45 M (USD)21.51as on Dec 31, 2025
- Net Profit$158.69 M (USD)9.07as on Dec 31, 2025
- EBITDA$233.8 M (USD)8.78as on Dec 31, 2025
- Total Equity Funding$345M (USD)
in 6 rounds
- Latest Funding Round$200M (USD), Debt – Conventional
Jan 2020
- InvestorsFidelity Investments
& 9 more
- Employee Count268
- Investments & Acquisitions
Products & Services of Harmony Biosciences
Harmony Biosciences offers a comprehensive portfolio of products and services, including ZYN002.
Treatment for Fragile X Syndrome in neurological patients
Funding Insights of Harmony Biosciences
Harmony Biosciences has successfully raised a total of $345M across 6 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $200 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $345M
- Total Rounds 6
- Last Round Debt – Conventional — $200M
- First Round $270M
(Sep 2017)
- Investors Count 10
All 6 funding rounds of Harmony Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $200M | Debt – Conventional | – | – | |
| Aug 2019 | $50M | Series E | – | – | – |
| Mar 2019 | $200M | Debt – Conventional | – | – | |
| Jun 2018 | Series D | – | Aisling Capital | – | |
| Jan 2018 | $25M | Series D | – | – | – |
| Sep 2017 | $270M | Series D | – | Valor Equity Partners, HBM Healthcare Investments | – |
10 investors in total: 10 institutional.
Investors in Harmony Biosciences
Harmony Biosciences has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, Orbimed and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Private equity firm | valorep.com | Chicago, United States | ||
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
A life sciences investment firm focused on novel therapeutics is operated. | 2011 | venbio.com | San Francisco, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Corporate backed venture capital firm investing in life sciences sector | nanfunglifesciences.com | San Francisco, United States | ||
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States |
Investor details for Harmony Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Harmony Biosciences
84 people are tracked at Harmony Biosciences (55 in leadership, 8 in board & advisors, 21 in team); the tracked headcount is 268.
| Name | Role | Group |
|---|---|---|
Paul Ferguson | Director Of Accounting Operations | Leadership |
Roger L Sharp | Vice President Of Sales | Leadership |
Alexis DeAngelo | Executive Administrative Assistant to Chief Executive Officer | Leadership |
Mary Bordic | Director, Medical Information | Leadership |
Amit Ray | Senior Medical Director, Clinical Development & Strategy | Leadership |
Cindy Dempsey | Sr Director, Head Medical Science Liaison | Leadership |
Marisa Sharkey | Senior Director, Corporate Communications | Leadership |
Bill Jerdon | Director, Internal Control And Financial Policy | Leadership |
Elsie Melsopp | Executive Director Of Manufacturing Development | Leadership |
Michael Faia | Head Of R&d Portfolio Management | Leadership |
Michelle Manuel | Director Clinical Operations | Leadership |
Bri McWilliams | Associate Director, Trade And Distribution | Leadership |
Christian Emering | Director External Communications | Leadership |
Laura Clark-Kelly | Senior Director, Value And Reimbursement | Leadership |
Amber Walker | Executive Director Trade And Distribution | Leadership |
Matthew Whisner | Director Of Trade And Distribution | Leadership |
Melissa Toler | Executive Director, Medical Affairs Operations | Leadership |
Salvatore P. Insana | Senior Director, Clinical Development And Strategy | Leadership |
Kristen Graesser Bzdek | Senior Medical Director Clinical Development | Leadership |
Eric Bauer | Vice President | Leadership |
64 more people are available in the full profile.
Complete people profiles for Harmony Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Harmony Biosciences
Harmony Biosciences is a publicly listed company on the NASDAQ with ticker symbol HRMY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Aug 2020
- Listed onNASDAQ: HRMY
- Listed entityHarmony Biosciences Holdings, Inc.
- Exchange sectorHealth technology
- ISINUS4131971040
- Share price$37.03 (-3.14% on the day) · 2026-10-13
- Market capitalisation$2.16B
- Price to earnings12.0
- EPS (diluted, trailing year)$3.09
- Volume (last session)1,419,022
Financials of Harmony Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $868.5M | $158.7M | $233.8M |
| 2024 | $714.7M | $145.5M | $214.9M |
| 2023 | $582.0M | $128.8M | $216.4M |
| 2022 | $437.9M | $181.5M | $143.6M |
| 2021 | $305.4M | $34.6M | $106.4M |
Detailed financial statements for Harmony Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Harmony Biosciences
Harmony Biosciences has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Zynerba Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Transdermal cannabinoid therapies are developed for neurological disorders. | zynerba.com | Devon, United States | 2007 | Aug 2023 | •••• |
Complete acquisition details for Harmony Biosciences
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Harmony Biosciences
5 dated milestones of Harmony Biosciences across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Harmony Biosciences is founded.
- Funding First funding round of $270.0M.
- Funding Latest funding round, Debt – Conventional, of $200.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Zynerba Pharma.
Competitors of Harmony Biosciences
Harmony Biosciences has 3 listed competitors in our database, 2 of them funded. They include QurAlis, Passage Bio and MindMed.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| quralis.com | 2016 | Cambridge, United States | $155.45M | 38 | Drugs and CSF devices are developed for ALS treatment. | |
| passagebio.com | 2017 | Philadelphia, United States | $225.5M | 58 | Gene therapies for CNS rare diseases are developed. | |
| mindmed.co | 2019 | New York, United States | 74 | Psychedelic-based therapies for brain health disorders are developed. |
Detailed competitors of Harmony Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Harmony Biosciences
The website of Harmony Biosciences (harmonybiosciences.com) receives about 10.2K visits a month and ranks #1,919,760 among all websites worldwide, #2,619 in Biotechnology and Pharmaceuticals.
- Monthly visits10.2K
▼ 20% vs previous month
- Unique visitors5.2K
per month
- Global rank#1,919,760
among all websites
- Category rank#2,619
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit2.0
- Average visit4 min 32 sec
- DevicesDesktop 34% · Mobile 66%
Top companies in Rare Diseases
3 companies that operate in the same segment as Harmony Biosciences (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Harmony Biosciences
Complete news archive for Harmony Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Harmony Biosciences
Harmony Biosciences was founded in 2017.
Harmony Biosciences is headquartered in Plymouth Meeting, United States. It is registered at Plymouth Meeting, Pennsylvania, United States.
Harmony Biosciences is a funded company, having raised a total of $345M across 6 funding rounds to date. The company's 1st funding round was a Series D of $270M, raised on Sep 2017.
Harmony Biosciences has 268 employees.
Annual revenue of Harmony Biosciences is $868.45M as on Dec 31, 2025.
Developer of therapeutics for rare neurological diseases. The company is engaged in the research, development, and commercialization of novel treatments for rare diseases mainly CNS disorders including Wakix for Narcolepsy.
Harmony Biosciences's top competitors include QurAlis, MindMed and Passage Bio.
Harmony Biosciences offers ZYN002.
Yes, Harmony Biosciences is publicly traded on NASDAQ under the ticker symbol HRMY.
Harmony Biosciences has made 1 acquisition, including Zynerba Pharma.
Harmony Biosciences has 10 investors. Key investors include Fidelity Investments, Orbimed, HBM Healthcare Investments, CRG, and Aisling Capital.
Harmony Biosciences operates through Harmony Biosciences Management, Inc..